DSM Sells Michigan Manufacturing Facility to Albemarle
Albemarle Corporation signed an agreement with DSM Pharmaceutical Products to buy the assets and the fine chemistry services and pharma chemicals business associated with DSM's South Haven, Michigan facility.
South Haven, MI (Sept. 20)-Albemarle Corporation (Richmond, VA, www.albemarle.com) signed an agreement with DSMPharmaceutical Products (Parsippany, NJ, www.dsm.com) to buy the assets and the fine chemistry services and pharma chemicals business associated with DSM's South Haven, Michigan facility.
The facility will become part of Albemarle's fine chemicals division, a provider of CGMP and non-GMP custom chemical manufacturing services, ingredients, and intermediates to the pharmaceutical industry.
DSM had announced in December 2005 its decision to close or divest the South Haven site, which is focused on the production of generic active pharmaceutical ingredients. This divestiture is part of DSM's asset-base restructuring, which also included the mothballing of the DSM Biologics facilities in Montreal, Canada in the beginning of 2006.
Completion of the acquisition is targeted for Sept. 30, 2006.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
